Thermalin Inc.

Thermalin is developing next-generation insulins to fill gaps in a rapidly growing $25B market. Our new molecules include ultra-concentrated, ultra-rapid-acting/fast offset meal-time and pump insulin ($7B addressable), ultra-heat stable, long- and biphasic ($8B+) insulin, glucose responsive insulins, and dermal patch insulin. Thermalin has partnered two of these programs with Sanofi and will be seeking partners for the other programs.